Sharechat Logo

Daily ShareChat: EBOS Group

By Jenny Ruth

Tuesday 15th March 2011

Text too small?
 Jenny Ruth

Medical supplies company EBOS Group's shares appear fairly priced but an acquisition could change that perception, says McDouall Stuart.

It values EBOS shares at $7.29.

"With cash of $17 million, no debt and a $106 million funding facility in place, the company is focused on further acquisition opportunities. A broad range of opportunities are being evaluated," the broker says.

"The company has a five-year goal of matching New Zealand revenue in Australia. With Australian sales at just under 10% of New Zealand sales, a major acquisition is likely in the near to medium term," it says.

Since directors, senior management and their associates own about 30% of EBOS and they have more than 20 years of successful stewardship of the company, "both the chief executive (Mark Waller) and chief financial officer (Dennis Doherty) should ensure that any acquisition is well considered."

EBOS' involvement in the healthcare industry in Australia and New Zealand will continue to benefit from population demographics, McDouall Stuart says.

It is forecasting net profit will fall to $24.8 million in the year ending June from $25.5 million the previous year before rising to $28.1 million in 2012 and $30.9 million in 2013.

"The company is optimistic of its prospects in the resilient health sector and is confident of its growth prospects."

 

Recommendation: Hold.

DISCLAIMER: To the extent that any of the content above constitutes advice, it is general advice that has been prepared without reference to investor’s objectives, financial situation or needs. Before acting on any advice, investors should consider the appropriateness of the advice and IRG recommend that investors should obtain appropriate financial, legal and taxation advice before making any financial investment decision. The report is based on information compiled from public information and private research. IRG have completed the report on a best endeavours basis and do not accept any liability of loss or damage. IRG suggest that clients use this as part of a decision making process and check key data before making any investment decisions.
Employees may have an interest in the securities discussed in this report.



  General Finance Advertising    

Comments from our readers

No comments yet

Add your comment:
Your name:
Your email:
Not displayed to the public
Comment:
Comments to Sharechat go through an approval process. Comments which are defamatory, abusive or in some way deemed inappropriate will not be approved. It is allowable to use some form of non-de-plume for your name, however we recommend real email addresses are used. Comments from free email addresses such as Gmail, Yahoo, Hotmail, etc may not be approved.

Related News:

Ebos still hungry for acquisitions after $1.1 bln Symbion deal, Waller says
Ebos meets prospectus forecast with 5.5 percent gain in FY profit
Ebos shareholders approve $1.1 billion purchase of Symbion
Ebos grabs scale with $1.1 bln purchase of Aussie pharma distributor Symbion
Ebos kicks tyres on potential acquisitions
Ebos lifts profit by 19%, targets growth in animal health
Ebos funding line smaller than previously flagged at $135 mln
Ebos Group
Ebos backs off British purchase, evaluates "significant" Australasian asset
Ebos reports higher profit, looks for acquisitions